Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient

Patent Citations (58)

Non-Patent Literature (118)

• Asano, R., et al., “The advance on the antibody therapy—the expectation to the clinical application,” Igaku no Ayumi 211:723-727, Maruzen Co Ltd., Tokyo, Japan (2004).Applicant
• Baba, I., et al., “Involvement of Deregulated Epiregulin Expression in Tumorigenesis in Vivo through Activated Ki-Ras Signaling Pathway in Human Colon Cancer Cells,” Cancer Res. 60:6886-6889, American Association for Cancer Research, Philadelphia, PA (2000).Applicant
• Hanai, Nobuo, “Antibody Modification and Transgenic Mice,” Biotherapy 17:415-421, Kluwer Academic Publishers, Dordrecht, Netherlands (2003).Applicant
• Minn, A.J., et al., “Genes that mediate breast cancer metastasis to lung,” Nature 436:518-524, Nature Publishing Group, London, England (Jul. 2005).Applicant
• R&D Systems, Inc., “Monoclonal Anti-human Epiregulin Antibody,” R&D Systems Catalog, Catalog No. MAB1425, 1 page, Minneapolis, MN (2003).Applicant
• R&D Systems, Inc., “Anti-human Epiregulin Antibody,” R&D Systems Catalog, Catalog No. AF1195, 2 pages, Minneapolis, MN (2003).Applicant
• Shirakata, Y., et al., “Epiregulin, a Novel Member of the Epidermal Growth Factor Family, Is an Autocrine Growth Factor in Normal Human Keratinocytes,” J. Biol. Chem. 275:5748-5753, American Society for Biochemistry and Molecular Biology, Bethesda, MD (2000).Applicant
• Shirasawa, S., et al., “Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage,” Proc. Natl. Acad. Sci. U.S.A. 101:13921-13926, National Academy of Sciences, Washington, DC (2004).Applicant
• Sunanaga, N., et al., “Haigan ni okeru Epiregulin Idenshi no Hatsugen ni tsuite no Kento,” The Journal of the Japanese Respiratory Society 45:167, The Japanese Respiratory Society (2007).Applicant
• Takahashi, M., et al., “Epiregulin as a Major Autocrine/Paracrine Factor Released From ERK- and p38MAPK-Activated Vascular Smooth Muscle Cells,” Circulation 108:2524-2529, American Heart Association, Inc. (2003).Applicant
• Toyoda, H., et al., “Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family,” Biochem. J. 326:69-75, Portland Press, London, England (1997).Applicant
• Toyoda, H., et al., “Epiregulin. A Novel Epidermal Growth Factor With Mitogenic Activity for Rat Primary Hepatocytes,” J. Biol. Chem. 270:7495-7500, American Society for Biochemistry and Molecular Biology, Bethesda, MD (1995).Applicant
• Zhu, Z., et al., “Epiregulin Is Up-Regulated in Pancreatic Cancer and Stimulates Pancreatic Cancer Cell Growth,” Biochem. Biophys. Res. Commun. 273:1019-1024, Academic Press, Burlington, MA (2000).Applicant
• International Search Report for International Patent Application No. PCT/JP2007/069988, filed Oct. 12, 2007, mailed on Nov. 20, 2007, Japanese Patent Office, Tokyo, Japan (Not a Counterpart Application).Applicant
• Koo, B.-H. and Kim, D.-S., “Factor Xa Induces Mitogenesis of Vascular Smooth Muscle Cells via Autocrine Production of Epiregulin,” J. Biol. Chem. 278(52):52578-52586, The American Society for Biochemistry and Molecular Biology, Inc., United States (2003).Applicant
• Friedberg, J.W., “Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy,” Hematology 2005:329-334 , American Society of Hematology (2005).Applicant
• Dean. C., et al., “Immunotherapy With Antibodies to the EGF Receptor,” Int. J. Cancer Supplement 8:103-107, Wiley-Liss, Inc., United States (1994).Applicant
• Force, T., et al., “Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition,” Nature Reviews Cancer 7:332-334, Nature Publishing Group, England (2007).Applicant
• Higashiyama, S., et al., “Membrane-anchored growth factors, the epidermal growth factor family: Beyond receptor ligands,” Cancer Sci. 99(2):214-220, Japanese Cancer Association, Japan (2008).Applicant
• Ito, M., et al., “Expression of several growth factors and their receptor genes in human colon carcinomas,” Virchows Archiv B Cell Pathol. 59:173-178, Springer-Verlag, Germany (1990).Applicant
• Johnson, G.R., et al., “Autocrine Action of Amphiregulin in a Colon Carcinoma Cell Line and Immunocytochemical Localization of Amphiregulin in Human Colon,” J. Cell Biol. 118(3):741-751, The Rockefeller University Press, United States (1992).Applicant
• Lacouture, M.E., “Mechanisms of cutaneous toxicities to EGFR inhibitors,” Nature Reviews Cancer 6:803-812, Nature Publishing Group, England (2006).Applicant
• Lu, Y., et al., “Immunogene Therapy of Tumors with Vaccine Based on Xenogenic Epidermal Growth Factor Receptor,” J. Immunol. 170:3162-3170, The American Association of Immunologists, Inc., United States (2003).Applicant
• Modjtahedi, H., et al., “Anti-EGFR Monoclonal Antibodies Which Act As EGF, TGFα, HB-EGF and BTC Antagonists Block the Binding of Epiregulin to EGFR-Expressing Tumors,” Int. J. Cancer 75:310-316, Wiley-Liss, Inc., United States (1998).Applicant
• Qian, J.F., et al., “Human transforming growth factor alpha: sequence analysis of the 4.5-kb and 1.6-kb mRNA species,” Gene 132:291-296, Elsevier Science Publishhers B.V., Netherlands (1993).Applicant
• Schneider, M.R. and Wolf, E., “The Epidermal Growth Factor Receptor Ligands at a Glance,” J. Cell Physiol. 218:460-466, Wiley-Liss, Inc., United States (2008).Applicant
• Seth, D., et al., “Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-α in human prostate cancer cells,” Br. J. Cancer 80(5/6):657-669, Cancer Research Campaign, England (1999).Applicant
• Tejpar, S., et al., “Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study,” Lancet Oncol. 8:387-394, Lancet Publishing Group, England (2007).Applicant
• Tiel Groenestege, W.M., et al., “Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia,” J. Clin. Invest. 117(8):2260-2267, American Society for Clinical Investigation, United States (2007).Applicant
• Willmarth, N.E., and Ethier, S.P., “Autocrine and Juxtacrine Effects of Amphiregulin on the Proliferative, Invasive, and Migratory Properties of Normal and Neoplastic Human Mammary Epithelial Cells,” J. Biol. Chem. 281(49):37728-37737, The American Society for Biochemistry and Molecular Biology, Inc., United States (2006).Applicant
• Wilson, K.J., et al., “Functional selectivity of EGF family peptide growth factors: Implications for cancer,” Pharmacol. Ther.122(1):1-8, Elsevier B.V., Netherlands (2009).Applicant
• Unverified English language translation of WO 2008/047723 A1, published Jun. 24, 2008.Applicant
• Nicholson, B.E. et al., “Profiling the Evolution of Human Metastatic Bladder Cancer,” Cancer Res. 64:7813-7821, American Association for Cancer Research, United States (2004).Applicant
• Kurachi, H. et al., “Importance of Transforming Growth Factor α/Epidermal Growth Factor Receptor Autocrine Growth Mechanism in an Ovarian Cancer Cell Line in Vivo,” Cancer Res. 51:5956-5959, American Association for Cancer Research, United States (1991).Applicant
• Zhang, J. et al., “Intratumoral Epiregulin Is a Marker of Advanced Disease in Non-Small Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells,” Cancer Prev. Res. 1(3):201-207, American Association for Cancer Research, United States (2008).Applicant
• Normanno, N. et al., “Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment,” Endocrine-Related Cancer 10:1-21, Society for Endocrinology, United Kingdom (2003).Applicant
• Tamura, M. et al., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only,” J. Immunol. 164:1432-1441, The American Association of Immunologists (2000).Applicant
• Sato, K., et al., “Solution structure of epiregulin and the effect of its C-terminal domain for receptor binding affinity,” FEBS Letters 553:232-238, Elsevier Science B.V., Netherlands (2003).Applicant
• Kairemo, K.J.A., “Positron Emission Tomography of Monoclonal Antibodies,” Acta Oncol. 32:825-830, Informa Healthcare, London (1993).Applicant
• NCBI GenBank Accession No. AAX36706, Hines, L., et al., Entry Date Mar. 16, 2005.Applicant
• NCBI GenBank Accession No. AAF61510, Cassady-Cain, R.L. and Kaushik, A.K., Entry Date May 2, 2006.Applicant
• NCBI GenBank Accession No. AAR90995, Liang, Z., et al., Entry Date Mar. 15, 2004.Applicant
• Unverified English language translation of Asano, R., et al., “The Advance on the Antibody Therapy—the Expectation to the Clinical Application,” Igaku no Ayumi 211:723-727, Maruzen Co Ltd., Tokyo, Japan (2004).Applicant
• Unverified English language translation of Sunanaga, N., et al., “Haigan ni okeru Epiregulin Idenshi no Hatsugen ni tsuite no Kento,” The Journal of the Japanese Respiratory Society 45:167, The Japanese Respiratory Society, Japan (2007).Applicant
• Bugelski, P.J., et al., “Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies,” Human & Experiemental Toxicology, 19:230-243, Nature America, Inc., United States (2000).Applicant
• Sandusky, G.E., et al., “Use of Monoclonal Antibodies to Human Lymphocytes to Identify Lymphocyte Subsets in Lymph Nodes of the Rhesus Monkey and the Dog,” J. Med. Primatol 15:441-451, Alan R. Liss, Inc., United States (1986).Applicant
• Schlereth, B., et al., “T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti CD3 single-chain antibody construct,” Cancer Immunol Immunother 55:503-514, Springer-Verlag, Germany (2006).Applicant
• Uda, A., et al., “CD3 polymorphism in cynomolgus monkeys (Macaca fascicularis),” J. Med. Primatol, 30:141-147, Munksgaard, Copenhagen, Denmark (2001).Applicant
• International Search Report for International Patent No. PCT/JP2012/084042, filed Dec. 28, 2012, mailed on Feb. 5, 2013, Japanese Patent Office, Tokyo, Japan.Applicant
• Beckman, R. A., et al., “Antibody Constructs in Cancer Therapy,” Cancer 109(2):170-179, American Cancer Society, United States (2007).Applicant
• Bischoff, R. and Kolbe, H.V., “Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology,” Journal of Chromatography B 662:261-278, Elsevier Science B.V., Netherlands (1994).Applicant
• Blanche, F., et al,, “Stabilization of Recombinant Adenovirus: Site-Directed Mutagenesis of Key Aspargine Residues in the Hexon Protein,” Analytical Biochemistry 297(1):1-9, Academic Press, United States (2001).Applicant
• Brorson, K., et al., “Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies,” The Journal of Immunology 163(12):6694-6701, The American Association of Immunologists (1999).Applicant
• Brummell, D.A., et al., “Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis: role of the heavy-chain CDR3 residues,” Biochemistry 32(4):1180-1187, American Chemical Society, United States (1993) (Abstract).Applicant
• Burks, E.A., et al., “In vitro scanning saturation mutagenesis of an antibody binding pocket,” Proc Natl Acad Sci USA 94:412-417, The National Academy of Sciences of the USA (1997).Applicant
• Cacia, J., et al., “Isomerization of an Aspartic Acid Residue in the Complementarity-Determining Regions of a Recombinant Antibody to Human IgE: Identification and Effect on Binding Affinity,” Biochemistry 35:1897-1903, American Chemical Society (1996).Applicant
• Casset, F., et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochemical and Biophysical Research Communications 307:198-205, Elsevier Science, United States (2003).Applicant
• Céspedes, M.V., et al., “Mouse models in oncogenesis and cancer therapy,” Clin Transl Oncol 8(5):318-329, Springer Italia, Italy (2006).Applicant
• Chen, Y., et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” J Mol Biol 293:865-881, Academic Press, United States (1999).Applicant
• Chothia, C. and Lesk, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”J Mol Biol 196:901-917, Academic Press, United States (1987).Applicant
• Chothia, C., et al., “Structural Repertoire of the Human VH Segments,” J Mol Biol 227(3):799-817, Academic Press, United States (1992).Applicant
• Colman, P.M., “Effects of amino acid sequence changes on antibody-antigen interactions,” Research in Immunology 145:33-36, Elsevier Science, United States (1994).Applicant
• Dennis, C., “Cancer: Off by a whisker,” Nature 442:739-741, Nature Publishing Group, England (2006).Applicant
• De Pascalis, R., et al., “Grating of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” The Journal of Immunology 169:3076-3084, The American Association of Immunologists, United States (2002).Applicant
• Flessner, M.F., et al., “Resistance of Tumor Interstitial Pressure to the Penetration of Intraperitoneally Delivered Antibiodies into Metastatic Ovarian Tumors,” Clin Cancer Res 11:3117-3125, American Association for Cancer Research (2005).Applicant
• Fujimori, K., et al., “A Modeling Analysis of Monoclonal Antibody Percolation Through Tumors: A Binding-Site Barrier,” J Nucl Med 31:1191-1198, Society of Nuclear Medicine, United States (1990).Applicant
• Geiger, T. and Clarke, S., “Deamidation, Isomerization, and Racemization at Asparaginyl and Aspartyl Residues in Peptides,” The Journal of Biological Chemistry 262(2):785-794, The American Society of Biological Chemists, Inc., United States (1987).Applicant
• Goolcharran, C., et al., “The Effects of a Histidine Residue on the C-Terminal Side of Asparaginyl Residue on the Rate of Deamidation Using Model Pentapeptides,” Journal of Pharmaceuitical Sciences 89(6):818-825, Wiley-Liss, United States (2000).Applicant
• Harris, R.J., et al., “Identification of multiple sources of charge heterogeneity in a recombinant antibody,” Journal of Chromatography B 752:233-245, Elsevier Science B.V., Netherlands (2001).Applicant
• Holm, P., et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,” Molecular Immunology 44:1075-1084, Elsevier Ltd., England (2007).Applicant
• Jain, R.K., “Physiological Barriers to Delivery of Monoclonal Antibodies and Other Macromolecules in Tumors,” Cancer Res 50:814s-819s, American Association for Cancer Research (1990).Applicant
• Jang, J.-Y., et al., “The structural basis for DNA binding by an anti-DNA autoantibody,” Molecular Immunology 35:1207-1217, Pergamon, England (1998).Applicant
• Kobayaski, H., et al., “Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody,” Protein Engineering 12(10):879-884, Oxford University Press, England (1999).Applicant
• Kumar, S., et al., “Molecular Cloning and Expression of the Fabs of Human Autoantibodies in Escherichia coli,” The Journal of Biological Chemistry 275(45):35129-35136, The American Society for Biochemistry and Molecular Biology, Inc., United States (2000).Applicant
• Kuntz, E., et al., “Effect of epiregulin on pancreatic beta cell growth and insulin secretion,” Growth Factors 23(4):285-293, Harwood Academic Publishers, England (2005) (Abstract).Applicant
• MacCallum, R.M., et al., “Anitbody-antigen Interactions: Contact Analysis and Binding Site Topography,” J Mol Biol 262:732-745, Academic Press Limited, United States (1998).Applicant
• Manning, M.C., et al., “Stability of Protein Pharmaceuticals,” Pharmaceutical Research 6(11):903-918, Kluwer Academic/Plenum Publishers, United States (1989).Applicant
• NCBI Reference Sequence, Accession No. NP—001423, “epiregulin”, Entry Date Apr. 2005.Applicant
• Robinson, N.E. and Robinson, A.B., “Molecular clocks,” PNAS 98(3):944-949, National Academy of Sciences, United States (2001).Applicant
• Robinson, N.E. and Robinson, A.B., “Deamidation of human proteins,” PNAS 98(22):12409-12413, National Academy of Sciences, United States (2001).Applicant
• Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding speficity,” PNAS 79:1979-1983, National Academy of Sciences, United States (1982).Applicant
• Rudnick, S.I. and Adams, G.P., “Affinity and Avidity in Antibody-Based Tumor Targeting,” Cancer Biotherapy and Radiopharmaceuticals 24(2):155-161, Mary Ann Liebert, Inc, United States (2009).Applicant
• Scotchler, J.W. and Robinson, A.B., “Deamidation of Glutaminyl Residues: Dependence on pH, Temperature, and Ionic Strength,” Analytical Biochemistry 59:319-322, Academic Press, Inc., United States (1974).Applicant
• Smith-Gill, S.J., et al., “Contributions of Immunoglobulin Heavy and Light Chains to Antibody Specificity for Lysozyme and Two Haptens,” The Journal of Immunology 139:4135-4144, The American Association of Immunologists (1987).Applicant
• Song, M-K., et al., “Light Chain of Natural Antibody Plays a Dominant Role in Protein Antigen Binding,” Biochemical and Biophysical Research Communications 268:390-394, Academic Press, United States (2000).Applicant
• Spinelli, G.P., et al., “Long-Term Survival in Metastatic Pancreatic Cancer. A Case Report and Review of the Literature,” J Pancreas (Online) 7(5):486-491, E.S. Burioni Ricerche Bibliografiche, Italy (2006).Applicant
• Sugo, I., et al., “Study on structural properties of antibody pharmaceuticals (3)—Activity Reduction Cause by Deamidation of Asn Residues and Molecular Design for Preventing the Reduction,” Proc. 124th Ann. Meeting Pharmacol. Soc. Japan (Nihon Yakugakukai Dai124nenki Osaka 2004 youshishyu), 30[p. 2]III-389, p. 103 (Mar. 5, 2004) (Translation Included).Applicant
• Talmadge, J.E., et al., “Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer,” The American Journal of Pathology 170(3):793-804, The American Society for Investigative Pathology, United States (2007).Applicant
• Thurber, G.M., et al., “Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance,” Advanced Drug Delivery Reviews 60:1421-1434, Elsevier B.V., Netherlands (2008).Applicant
• Tomizawa, H., et al., “Stabilization of lysozyme against irreversible inactivation by alterations of the Asp-Gly sequences,” Protein Engineering 8(10):1023-1028, Oxford University Press, England (1995).Applicant
• Tyler-Cross, R. and Schirch, V. “Effects of Amino Acid Sequence, Buffers, and Ionic Strength on the Rate and Mechanism of Deamidation of Asparagine Residues in Small Peptides,” The Journal of Biological Chemistry 266(33):22349-22556, The American Society for Biochemistry and Molecular Biology, Inc., United States (1991).Applicant
• Vajdos, F.F., et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J Mol Biol 320:415-428, Elsevier Science Ltd., England (2002).Applicant
• Voskoglou-Nomikos, T., et al., “Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models,” Clinical Cancer Research 9:4227-4239, The American Association for Cancer Research, United States (2003).Applicant
• Ward, E.S., et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli,” Nature 341:544-546, Nature Publishing Group, England (1989).Applicant
• Wu, H. et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J Mol Biol 294:151-162, Academic Press, United States (1999).Applicant
• Nautiyal, J. et al., “Targeting EGFRs and Src signaling with a modified ectodomain of human EGFR (EBIP) and dasatinib in breast cancer,” Cancer Research 69(2) Suppl 1:3069, American Association for Cancer Research, United States (2008) (Abstract #3069).Applicant
• Perkins, M. et al., “Determination of the Origin of Charge Heterogeneity in a Murine Monoclonal Antibody,” Pharmaceutical Research 17(9):1110-1117, Plenum Publishing Corporation, United States (2000).Applicant
• International Preliminary Report on Patentability of the International Searching Authority for International Application No. PCT/JP2007/069988, mailed on Apr. 28, 2009, The International Bureau of WIPO, Switzerland (Not a Corresponding Application).Applicant
• International Preliminary Report on Patentability of the International Searching Authority for International Application No. PCT/JP2010/059008, mailed on Jul. 6, 2010, The International Bureau of WIPO, Switzerland (Not a Corresponding Application).Applicant
• International Search Report for International Application No. PCT/JP2010/059008, mailed on Jul. 6, 2010, Japanese Patent Office, Tokyo Japan (Not a Corresponding Application).Applicant
• Supplementary European Search Report in European Patent Application No. 07 82 9724, mailed on Jul. 29, 2010, European Patent Office, Munich, Germany (Not a Corresponding Application).Applicant
• Co-pending Application, U.S. Appl. No. 14/873,861 inventors Yoshida et al., filed Oct. 2, 2015 (Not Yet Published).Applicant
• An, S.-J., et al., “Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status,” PLoS One 7(6):e40109, 13 pages, Open Access Article (2012).Applicant
• International Search Report for International Application No. PCT/JP2014/066512, Japanese Patent Office, Japan, mailed on Aug. 12, 2014, 2 pages (Not a Corresponding Application).Applicant
• Gold, K.A., “New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy,” Clinical Cancer Research 18(11):3002-3007, American Association for Cancer, United States (2012).Applicant
• Langer, C.J., et al., “The Evolving Role of Histology in the Management of Advanced Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology 28(36):5311-5320, American Society of Clinical Oncology, United States (2010).Applicant
• Pennell, N.A., “Selection of chemotherapy for patients with advanced non-small cell lung cancer,” Cleveland Clinic Journal of Medicine 79:e-S46-e-S50, Cleveland Clinic Educational Foundation, United States (2012).Applicant
• Sandler, A., et al., “Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer,” Journal of Thoracic Oncology 5(9):1416-1423, International Association for the Study of Lung Cancer, United States (2010).Applicant
• Co-Pending U.S. Appl. No. 14/900,928, inventors Suzuki, Masami, et al., Int'l filing date of Jun. 23, 2014 (Not Yet Published).Applicant
• Beidler, C.B., et al., “Generation and Activity of a Humanized Monoclonal Antibody That Selectively Neutralizes the Epidermal Growth Factor Receptor Ligands Transforming Growth Factor-α and Epiregulin,” The Journal of Pharmacology and Experimental Therapeutics 349:330-343, The American Society for Pharmacology and Experimental Therapeutics, United States (2014).Applicant
• Imanishi, K.-I., et al., “Inhibition of Growth of Human Lung Adenocarcinoma Cell Lines by Anti-Transforming Growth Factor-α Monoclonal Antibody,” Journal of National Cancer Institute 81:220-223, Oxford University Press, United States (1989).Applicant
• Jonker, D.J., et al., “Cetuximab for the Treatment of Colorectal Cancer,” The New England Journal of Medicine 357:2040-2048, Massachusetts Medical Society, United States (2007).Applicant
• Peggs, K.S., et al., “Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists,” Clinical and Experimental Immunology 157:9-19, British Society for Immunology, England (2009).Applicant
• Spano, J.P., et al., “Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives,” Annals of Oncology 16:189-194, European Society for Medical Oncology, Switzerland (2005).Applicant
• “Antibody Structure and Function,” in Immunology, Fifth Edition, Roitt, et al., Eds., pp. 110-111, C.V. Mosby Co., United States (1998).Applicant
• “Antibody Structure and Function,” in Immunology, Fifth Edition, Roitt, et al., Eds., pp. 80-81, C.V. Mosby Co., United States (1998).Applicant
• Imai-Nishiya, H., et al., “Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC,” BMC Biotechnology 7:84, BioMed Central Ltd., United Kingdom (2007).Applicant
• Schildbach, J.F., et al., “Modulation of antibody affinity by a non-contact residue,” Protein Science 2:206-214, Cambridge University Press, United States (1993).Applicant